Sifting the Iressa outcomes in Japan

Rates of interstitial lung disease in Japanese patients treated with AstraZeneca plc's Iressa are higher than in Iressa patients in other parts of the world. Last week, a group of experts assembled by the pharma company said it had found no direct relationship between Iressa and ILD. Instead, the difference appears to lie in the way the

Read the full 574 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE